Importantly, concurrent mutations in SMARCA4 and KEAP1, KRAS, or STK11 genes were found to further enhance the resistance of NSCLC tumors to immunotherapy [32–34]. The gene discussed is STK11; the disease is non-small cell lung carcinoma.